Your research can change the world
More on impact ›
Radionuclide Therapy is a fast-growing area of nuclear medicine. The section aims to publish innovative clinical and preclinical research on new therapeutic options as well as clinical studies using established radiopharmaceuticals. Our intention is to make active and critical contributions to science discourses.
Radionuclide Therapy is an exciting and fast growing area in the field of Nuclear Medicine. Several new radiopharmaceuticals achieved approval in the last years and many new and exciting therapy options are under investigation. The Radionuclide Therapy section aims to publish innovative clinical and preclinical research on new therapeutic options as well as clinical studies using established radiopharmaceuticals. Areas covered by this section include, but are not limited to:
All studies must contribute insights into treatments using radionuclides for therapy malignant or benign diseases. Particular focus should be put on effectiveness and safety of the treatments. Reports dealing with diagnosis or with non-radioactive therapy do not fall within the scope of this section and should be submitted to more specialized journals.
Indexed in: CLOCKSS, CrossRef, DOAJ, Google Scholar, OpenAIRE
Radionuclide Therapy welcomes submissions of the following article types: Brief Research Report, Case Report, Correction, Data Report, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Policy and Practice Reviews, Policy Brief, Review and Systematic Review.
All manuscripts must be submitted directly to the section Radionuclide Therapy, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact firstname.lastname@example.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact email@example.com